NF-κB Is Essential for Induction of CYLD, the Negative Regulator of NF-κB

  title={NF-$\kappa$B Is Essential for Induction of CYLD, the Negative Regulator of NF-$\kappa$B},
  author={Hirofumi Jono and Jae Hyang Lim and Lin-Feng Chen and Haidong Xu and Eirini Trompouki and Zhixing K. Pan and George Mosialos and Jian-Dong Li},
  journal={Journal of Biological Chemistry},
  pages={36171 - 36174}
The transcription factor NF-κB regulates genes involved in inflammatory and immune responses, tumorigenesis, and apoptosis. In contrast to the pleiotropic stimuli that lead to its positive regulation, the known signaling mechanisms that underlie the negative regulation of NF-κB are very few. Recent studies have identified the tumor suppressor CYLD, loss of which causes a benign human syndrome called cylindromatosis, as a key negative regulator for NF-κB signaling by deubiquitinating tumor… 

Figures from this paper

CYLD: a tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processes
  • S-C Sun
  • Biology
    Cell Death and Differentiation
  • 2010
This work has shown that a tumor suppressor DUB, cylindromatosis (CYLD), has a predominant role in the regulation of NF-κB, a transcription factor that promotes cell survival and oncogenesis and is subject to different mechanisms of regulation.
Ubiquitin Conjugation and Deconjugation in NF-κB Signaling.
The impact of the ubiquitin system on the NF-κB signaling network is reviewed by putting a focus on the enzymes that help to shape the plasticity of the NF -κB response by reviewing the mechanisms behind inactivation of deconjugating enzymes.
The RING ubiquitin E3 RNF114 interacts with A20 and modulates NF-κB activity and T-cell activation
The data indicate that RNF114 is a new partner of A2O involved in the regulation of NF-κB activity that contributes to the control of signaling pathways modulating T cell-mediated immune response.
TGF-β induces miR-182 to sustain NF-κB activation in glioma subsets.
It is found that TGF-β induced miR-182 expression, leading to prolonged NF-κB activation, and this findings uncover a plausible mechanism for sustained NF-β activation in malignant gliomas and may suggest a new target for clinical intervention in human cancer.
IκB kinase complexes: gateways to NF-κB activation and transcription
Nuclear IKK components have been found to act directly at the chromatin level of induced genes and to mediate responses to DNA damage, and IKK is engaged in cross talk with other pathways and confers functions independently of NF-κB.
CYLD: A Multifunctional Deubiquitinase
The nuclear factor-kappaB and c-Jun NH2-terminal kinase signaling pathways regulate diverse biological processes, including the immune and inflammatory response, cell growth, apoptosis, and tumor formation, and enhancing the understanding of the mechanisms that control signaling through these pathways is significant as it may enable development of specific treatments.
Current insights into the regulation of programmed cell death by NF-κB
There has been substantial progress in understanding NF-κB's mode of action in apoptosis and necrosis and the mechanisms that regulate its anti- vs proapoptotic activities, and recent developments shed new light on the role of NF-KappaB in many disease conditions including tumor development, tumor progression and anticancer treatment.


The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination
CYLD, a tumour suppressor that is mutated in familial cylindromatosis, interacts with NEMO, the regulatory subunit of IKK, strengthening the notion that ubiquitination is involved in IKK activation by TRAFs and suggesting that CYLD functions in this process.
CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members
Results indicate that CYLD is a negative regulator of the cytokine-mediated activation of NF-κB that is required for appropriate cellular homeostasis of skin appendages.
NF-κB regulation in the immune system
The role of NF-κB proteins as potential therapeutic targets in clinical applications and their role in the immune system and inflammatory diseases are discussed.
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB
It is reported here that inhibition of one of these enzymes, the familial cylindromatosis tumour suppressor gene (CYLD), having no known function, enhances activation of the transcription factor NF-κB, and this effect can be relieved by aspirin derivatives that inhibit NF-σB activity.
Duration of Nuclear NF-κB Action Regulated by Reversible Acetylation
It is demonstrated that the RelA subunit of NF-κB is subject to inducible acetylation and that acetylated forms of RelA interact weakly, if at all, with IκBα.
Activation of NF-κB by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK–IKKα/β–IκBα and MKK3/6–p38 MAP kinase signaling pathways in epithelial cells
The results demonstrate that NTHi activates NF-κB via TLR2–TAK1-dependent NIK–IKKα/β-IκBα and MKK3/6–p38 MAP kinase signaling pathways, and several key inflammatory mediators including IL-1β, IL-8, and tumor necrosis factor-α are up-regulated by N THi.
Synergistic activation of NF-κB by nontypeable Haemophilus influenzae and tumor necrosis factor α
It is shown that NTHi and TNF-α, when present together, synergistically induce NF-κB activation via two distinct signaling pathways: NF-kkB translocation-dependent and -independent pathways.
NF-κB in cancer: from innocent bystander to major culprit
Recent evidence indicates that NF-κB and the signalling pathways that are involved in its activation are also important for tumour development.